BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lowers the price target from $67 to $60.
BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform, Lowers Price Target to $60
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.